Acknowledgement
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2017R1A2B3004565).
References
- Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2, 1097-1105 https://doi.org/10.1177/1947601911423031
- Beck B, Driessens G, Goossens S et al (2011) A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 478, 399-403 https://doi.org/10.1038/nature10525
- Kim JY and Kim YM (2019) Tumor endothelial cells as a potential target of metronomic chemotherapy. Arch Pharm Res 42, 1-13 https://doi.org/10.1007/s12272-018-01102-z
- Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358, 2039-2049 https://doi.org/10.1056/NEJMra0706596
- Stoelting S, Trefzer T, Kisro J, Steinke A, Wagner T and Peters SO (2008) Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients. In Vivo 22, 831-836
- Kerbel RS and Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4, 423-436 https://doi.org/10.1038/nrc1369
- Rasanen M, Degerman J, Nissinen TA et al (2016) VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection. Proc Natl Acad Sci U S A 113, 13144-13149 https://doi.org/10.1073/pnas.1616168113
- Park M, Kim J, Kim T et al (2021) REDD1 is a determinant of low-dose metronomic doxorubicin-elicited endothelial cell dysfunction through downregulation of VEGFR-2/3. Exp Mol Med (In press)
- DeYoung MP, Horak P, Sofer A, Sgroi D and Ellisen LW (2008) Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22, 239-251 https://doi.org/10.1101/gad.1617608
- Lee DK, Kim JH, Kim J et al (2018) REDD-1 aggravates endotoxin-induced inflammation via atypical NF-κB activation. FASEB J 32, 4585-4599 https://doi.org/10.1096/fj.201701436R
- Karar J and Maity A (2011) PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci 4, 51 https://doi.org/10.3389/fnmol.2011.00051
- Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8, 128-135 https://doi.org/10.1038/nm0202-128
- Wang M, Xu Y, Wen GZ, Wang Q and Yuan SM (2019) Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression. Onco Targets Ther 12, 4643-4654 https://doi.org/10.2147/OTT.S205160
- Marumo T, Uchimura H, Hayashi M, Hishikawa K and Fujita T (2006) Aldosterone impairs bone marrow-derived progenitor cell formation. Hypertension 48, 490-496 https://doi.org/10.1161/01.HYP.0000235681.25685.cf
- Pitchford SC, Furze RC, Jones CP, Wengner AM and Rankin SM (2009) Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell 4, 62-72 https://doi.org/10.1016/j.stem.2008.10.017
- Aicher A, Heeschen C, Mildner-Rihm C et al (2003) Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9, 1370-1376 https://doi.org/10.1038/nm948
- Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y and Kerbel RS (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63, 4342-4346
- Bocci G, Francia G, Man S, Lawler J and Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 100, 12917-12922 https://doi.org/10.1073/pnas.2135406100
- Saif MW (2013) Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike? Cancer Manag Res 5, 103-115 https://doi.org/10.2147/CMAR.S45193
- Asahara T, Murohara T, Sullivan A et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967 https://doi.org/10.1126/science.275.5302.964
- Asahara T, Masuda H, Takahashi T et al (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85, 221-228 https://doi.org/10.1161/01.RES.85.3.221
- Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10, 145-147 https://doi.org/10.1038/nm988
- Murakami J, Li TS, Ueda K, Tanaka T and Hamano K (2009) Inhibition of accelerated tumor growth by blocking the recruitment of mobilized endothelial progenitor cells after chemotherapy. Int J Cancer 12, 1685-1692
- Sxton RA and Sabatini DM (2017) mTOR Signaling in growth, metabolism, and disease. Cell 169, 361-371
- Giraud S, Greco A, Brink M, Diaz JJ and Delafontaine P (2001) Translation initiation of the insulin-like growth factor I receptor mRNA is mediated by an internal ribosome entry site. J Biol Chem 276, 5668-5675 https://doi.org/10.1074/jbc.M005928200
- Chen TG, Chen JZ and Wang XX (2006) Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood. Cell Prolif 39, 117-125 https://doi.org/10.1111/j.1365-2184.2006.00375.x